Octagon Capital Advisors LP Trevi Therapeutics, Inc. Transaction History
Octagon Capital Advisors LP
- $301 Million
- Q1 2025
A detailed history of Octagon Capital Advisors LP transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Octagon Capital Advisors LP holds 3,322,000 shares of TRVI stock, worth $20.2 Million. This represents 6.95% of its overall portfolio holdings.
Number of Shares
3,322,000
Previous 4,637,076
28.36%
Holding current value
$20.2 Million
Previous $29.2 Million
28.36%
% of portfolio
6.95%
Previous 3.02%
Shares
2 transactions
Others Institutions Holding TRVI
# of Institutions
142Shares Held
85.3MCall Options Held
1.5MPut Options Held
304K-
Nea Management Company, LLC Timonium, MD11.4MShares$69.2 Million6.78% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA10.3MShares$62.5 Million4.06% of portfolio
-
Rubric Capital Management LP New York, NY4.54MShares$27.6 Million0.82% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.84MShares$23.4 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.49MShares$21.2 Million5.95% of portfolio
About Trevi Therapeutics, Inc.
- Ticker TRVI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 58,322,500
- Market Cap $355M
- Description
- Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...